Heme oxygenase (HO) activity is vital to a host of biological functions including cellular defense mechanisms, neuronal activity, vascular tone and male reproduction. The enzyme system oxidatively cleaves the heme molecule to biliverdin and carbon monoxide, a signal molecule. Biliverdin is reduced to bilirubin, an antioxidant, by biliverdin reductase (BVR). We have identified 3 HO isozymes: HO-1 (HSP-32), HO-2 and HO-3. HO-1 is exquisitely sensitive to environmental agents that cause oxidative stress and activate MAP kinase signal transduction pathways (e.g. 02 free radicals) as well as carcinogenesis and viral infections (e.g. Herpes, HIV). HO-2 and HO-3 are constitutively expressed. We have previously shown that HO-1 levels rapidly increase in response to oxidative stress both at the transcript and protein levels. The levels, however, rapidly decline with removal of the stimulus. Recently we identified HO-1 as a phosphoprotein. This type of protein modification can be of significance to protein stability and activity. Also, we discovered BVR to be a serine/threonine kinase and an activator of protein kinase C (PKC). PKC is upstream of the MAP kinase signaling pathway. On the other hand, we found that heme degradation product, biliverdin, is an in vivo inhibitor of HO activity and, a most effective inhibitor of PKC. Collectively, these findings lead us to hypothesize that a mechanism for the regulation of HO-1 expression by environmental oxidative stress involves both the kinase and the reductase activities of BVR: As a kinase, it activates the PKC/MAP kinase signaling pathway; and, as a reductase, it circumvents inhibition of the signaling pathway by biliverdin. We further hypothesize that phosphorylation is required for HO-1 activity and/or stability; hence, control of biliverdin production. These hypotheses will be tested by: 1) investigating the significance of HO-1 phosphorylation to its activity; and, examining whether rapid turnover of the induced HO-1 reflects a difference in its phosphorylation state under normal and induced conditions; 2) determining whether HO-1 is a phosphorylation substrate for BVR and/or PKC; 3) analyzing the regulatory role of BVR on induction of HO-1 gene expression through activation of the MAP kinase pathway; and; 4) assessing the effect of biliverdin on MAP kinase pathway activation. H202 will be utilized as the generator of 02 radicals. COS cells transfected with adenoviral vectors of effectors or their mutated counterparts will be used as the experimental model.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES012187-04
Application #
7061316
Study Section
Special Emphasis Panel (ZRG1-SSS-3 (02))
Program Officer
Balshaw, David M
Project Start
2003-07-15
Project End
2007-09-14
Budget Start
2006-05-03
Budget End
2007-09-14
Support Year
4
Fiscal Year
2006
Total Cost
$219,163
Indirect Cost
Name
University of Rochester
Department
Biochemistry
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Gibbs, Peter E M; Tudor, Cicerone; Maines, Mahin D (2012) Biliverdin reductase: more than a namesake - the reductase, its Peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C. Front Pharmacol 3:31
Miralem, Tihomir; Lerner-Marmarosh, Nicole; Gibbs, Peter E M et al. (2012) The human biliverdin reductase-based peptide fragments and biliverdin regulate protein kinase C? activity: the peptides are inhibitors or substrate for the protein kinase C. J Biol Chem 287:24698-712
Gibbs, Peter E M; Miralem, Tihomir; Lerner-Marmarosh, Nicole et al. (2012) Formation of ternary complex of human biliverdin reductase-protein kinase C?-ERK2 protein is essential for ERK2-mediated activation of Elk1 protein, nuclear factor-?B, and inducible nitric-oxidase synthase (iNOS). J Biol Chem 287:1066-79
Ding, Bo; Gibbs, Peter E M; Brookes, Paul S et al. (2011) The coordinated increased expression of biliverdin reductase and heme oxygenase-2 promotes cardiomyocyte survival: a reductase-based peptide counters *-adrenergic receptor ligand-mediated cardiac dysfunction. FASEB J 25:301-13
Gibbs, Peter E M; Miralem, Tihomir; Maines, Mahin D (2010) Characterization of the human biliverdin reductase gene structure and regulatory elements: promoter activity is enhanced by hypoxia and suppressed by TNF-alpha-activated NF-kappaB. FASEB J 24:3239-54
Maines, Mahin D (2010) Potential application of biliverdin reductase and its fragments to modulate insulin/IGF-1/MAPK/PI3-K signaling pathways in therapeutic settings. Curr Drug Targets 11:1586-94
Miralem, Tihomir; Gibbs, Peter E M; Revert, Fernando et al. (2010) Human biliverdin reductase suppresses Goodpasture antigen-binding protein (GPBP) kinase activity: the reductase regulates tumor necrosis factor-alpha-NF-kappaB-dependent GPBP expression. J Biol Chem 285:12551-8
Kapitulnik, Jaime; Maines, Mahin D (2009) Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci 30:129-37
Lerner-Marmarosh, Nicole; Miralem, Tihomir; Gibbs, Peter E M et al. (2008) Human biliverdin reductase is an ERK activator;hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc Natl Acad Sci U S A 105:6870-5
Tudor, Cicerone; Lerner-Marmarosh, Nicole; Engelborghs, Yves et al. (2008) Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem J 413:405-16

Showing the most recent 10 out of 20 publications